| 2.18 0.07 (3.32%) | 08-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.06  |
1-year : | 3.45 |
| Resists | First : | 2.62 |
Second : | 2.95 |
| Pivot price | 2.56 |
|||
| Supports | First : | 2.09 | Second : | 1.74 |
| MAs | MA(5) : | 2.28 |
MA(20) : | 2.58 |
| MA(100) : | 2.92  |
MA(250) : | 3.2 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 10.5 |
D(3) : | 12.2 |
| RSI | RSI(14): 30.3 |
|||
| 52-week | High : | 4.7 | Low : | 1.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LTRN ] has closed above bottom band by 8.3%. Bollinger Bands are 16.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.32 - 2.34 | 2.34 - 2.35 |
| Low: | 2.08 - 2.1 | 2.1 - 2.11 |
| Close: | 2.16 - 2.18 | 2.18 - 2.2 |
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Fri, 21 Aug 2026
LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
Fri, 21 Aug 2026
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript - The Globe and Mail
Fri, 21 Aug 2026
Here's Why We're A Bit Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation - Sahm
Mon, 17 Aug 2026
Lantern Pharma Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:LTRN) 2026-08-17 - Seeking Alpha
Fri, 14 Aug 2026
Is Lantern Pharma Inc (LTRN) Facing Increased Losses After Q2 Ea - GuruFocus
Fri, 14 Aug 2026
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 20.2 (%) |
| Held by Institutions | 22.5 (%) |
| Shares Short | 846 (K) |
| Shares Short P.Month | 929 (K) |
| EPS | -1.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -74.3 % |
| Return on Equity (ttm) | -401 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -1.34 |
| PEG Ratio | 0 |
| Price to Book value | -8.73 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|